These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1453 related articles for article (PubMed ID: 30538109)

  • 1. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 4. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
    Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
    Smith HG; Mansfield D; Roulstone V; Kyula-Currie JN; McLaughlin M; Patel RR; Bergerhoff KF; Paget JT; Dillon MT; Khan A; Melcher A; Thway K; Harrington KJ; Hayes AJ
    Clin Cancer Res; 2019 Jun; 25(11):3443-3454. PubMed ID: 30885937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
    de Vries CR; Monken CE; Lattime EC
    Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Immunological Treatment Effects of Virotherapy in Tumor Tissue.
    Das K; Urbiola C; Spiesschaert B; Mueller P; Wollmann G
    Methods Mol Biol; 2020; 2058():155-177. PubMed ID: 31486037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
    Wang S; Li Y; Xu C; Dong J; Wei J
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
    Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
    Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
    Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.
    Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS
    Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.